HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Singer, C. F Articles by Kubista, E. Search for Related Content PubMed PubMed Citation Articles by Singer, C. F Articles by Kubista, E.

Department of Senology and Ludwig Boltzmann-Institute of Clinical Experimental Oncology, University of Vienna, Austria
¹ Department of Obstetrics and Gynecology, Villach Hospital, Villach, Austria
² Department of Gynecopathology, Vienna, University of Vienna, Austria

(Requests for offprints should be addressed to C F Singer, Department of Obstetrics and Gynecology, Division of Senology, Vienna Medical University, Waehringer Guertel 18–20, A-1090 Vienna, Austria; Email: christian.singer{at}meduniwien.ac.at)

Tyrosine kinase (TK) inhibition has been identified as a promising strategy in the treatment of human malignancies and several synthetic inhibitors have been developed. While the selective blockage of specific TKs is highly effective in vitro, clinical results have been less impressive. It has been suggested that the simultaneous inhibition of multiple TKs might lead to more favorable therapeutic results in vivo. We have therefore performed a systematic analysis of intratumoral TK expression in order to identify potential targets for a simultaneous kinase inhibition. To this end, we have analyzed the protein expression of membrane-associated epidermal growth factor receptor (EGF-R), Her-2/neu, platelet-derived growth factor receptor (PDGF-R), insulin-like growth factor receptor (IGF-R), c-Kit and of cytoplasmatic c-Abl in 500 human tumors of epithelial, stromal and mesenchymal origin by immunohistochemistry, and found a distinct pattern of kinase expression: EGF-R, PDGF-R and c-Abl were expressed in the majority of malignant tumors, whereas c-Kit, Her-2/neu and IGF-R protein expression was considerably less frequent. Overall, the EGF-R protein expression was correlated with PDGF-R, c-Kit and c-Abl immunoreactivity (P = 0.003, P = 0.001 and P < 0.001, respectively). c-Abl was co-expressed with IGF-R and PDGF-R (P = 0.003 and P < 0.001, respectively). Kinase co-expression was also seen in tumor subgroups and was particularly significant in breast cancer where IGF-R protein was expressed together with PDGF-R and c-Abl (P = 0.003 and P = 0.004, respectively), and in colon cancer where PDGF-R was correlated with EGF-R (P < 0.001). With the exception of Her-2/neu expression and age, intra-tumoral TK expression was not associated with parameters such as grading or histological subtypes. Taken together, we have found a specific pattern of kinase co-expression and have identified several potential targets for a tumor-specific multimodal TK inhibition.

This article has been cited by other articles:

				A. Zeuner, M. Signore, D. Martinetti, M. Bartucci, C. Peschle, and R. De Maria Chemotherapy-Induced Thrombocytopenia Derives from the Selective Death of Megakaryocyte Progenitors and Can Be Rescued by Stem Cell Factor Cancer Res., May 15, 2007; 67(10): 4767 - 4773. [Abstract] [Full Text] [PDF]

				D. Srinivasan and R. Plattner Activation of Abl Tyrosine Kinases Promotes Invasion of Aggressive Breast Cancer Cells Cancer Res., June 1, 2006; 66(11): 5648 - 5655. [Abstract] [Full Text] [PDF]

				R Duncan, M J Vicent, F Greco, and R I Nicholson Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S189 - S199. [Abstract] [Full Text] [PDF]